Savara Inc. SVRA
4.99 USD +0.07 (+1.42%)
At closeNov 11, 2026, 5:55 PM EST
5.03 +0.04 +0.83%
After hours · Nov 11, 5:55 PM ET
4.92 Day range 5.21
4.03 52-week range 7.01
- YTD
- -17.25%
- 1 year
- +15.24%
News
benzinga.com Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The…
benzinga.com JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12 JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight rating and announces Price Target of $12.
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
benzinga.com Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data…
benzinga.com Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041 MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at…
benzinga.com Savara Q2 EPS $(0.16) Misses $(0.14) Estimate Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14)…
benzinga.com Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFO Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative…
benzinga.com Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking…- benzinga.com Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP At ATS 2026 International Conference -- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical…
- benzinga.com Savara Q1 EPS $(0.15) Misses $(0.14) Estimate Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 15.38 percent. This is a 25 percent decrease over losses of $(0.12) per…
- benzinga.com Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines…
- benzinga.com Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI…
- benzinga.com Savara Q4 EPS $(0.13), Inline Savara (NASDAQ:SVRA) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
- benzinga.com Savara Says U.S. FDA Will Not Hold Advisory Panel For MOLBREEVI BLA As Review Continues Toward August 22 PDUFA Date; Has Submitted The MAA To The EMA; Submission Of The MAA To The UK Medicines And MHRA Remains On Track By The End Of Q1 2026 -- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee ---- Company has Submitted the Marketing Authorization…
- benzinga.com Savara Announces FDA Files For Review Of Biologics License Application For MOLBREEVI As Autoimmune Pulmonary Alveolar Proteinosis Treatment; Sets Aug. 22 As Prescription Drug User Fee Act Target Action Date Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to…
- benzinga.com Savara Strengthens Balance Sheet With Access To ~$150M in Non-Dilutive Capital To Support MOLBREEVI Launch -- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --Savara Inc. (NASDAQ:SVRA) (the Company), a…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Savara And PANTHERx Rare Pharmacy Announce An Exclusive Distribution Agreement For MOLBREEVI PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical…
benzinga.com Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $10 HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $8 to $10.- benzinga.com Savara Resubmits MOLBREEVI BLA To FDA, With Fujifilm As Drug Substance Manufacturer -- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage…
- benzinga.com Wells Fargo Maintains Overweight on Savara, Raises Price Target to $9 Wells Fargo analyst Benjamin Burnett maintains Savara (NASDAQ:SVRA) with a Overweight and raises the price target from $7 to $9.
- benzinga.com European Patent Office Intends To Grant Savara Patent For Liquid Formulation Of MOLBREEVI -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device…
- benzinga.com Savara, PARI Granted European Patent Titled 'Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.' "This patent covers our drug-device combination through March 2043," said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Officer, Savara. "With 10 years of Orphan Drug regulatory exclusivity upon…
benzinga.com Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday - benzinga.com Oppenheimer Maintains Outperform on Savara, Raises Price Target to $9 Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $8 to $9.
- benzinga.com Citizens Maintains Market Outperform on Savara, Lowers Price Target to $10 Citizens analyst Jonathan Wolleben maintains Savara (NASDAQ:SVRA) with a Market Outperform and lowers the price target from $11 to $10.
- benzinga.com Savara Q3 EPS $(0.14) Misses $(0.13) Estimate Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 5.26 percent. This is a 27.27 percent decrease over losses of $(0.11) per…
- benzinga.com Reported Earlier, Savara Announces $130M Public Offering Including 23.8M Shares And 7.1M Pre-Funded Warrants Priced At $4.20 Per Share Savara intends to use the proceeds from the offering for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in
benzinga.com Savara Announces Common Stock Offering; Terms Not Disclosed Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of…- benzinga.com Savara Announces $75M Financing Agreement With RTW Investments Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW…
- benzinga.com Savara Presents New Data From Phase 3 IMPALA-2 Showing Molgramostim Beneficial In aPAP Patients Regardless Of Disease Severity – The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –– Changes in DLco%, the Primary Endpoint in IMPALA-2, Were…
- benzinga.com Guggenheim Maintains Buy on Savara, Raises Price Target to $11 Guggenheim analyst Vamil Divan maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $8 to $11.
- benzinga.com Oppenheimer Maintains Outperform on Savara, Raises Price Target to $8 Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $6 to $8.
- benzinga.com HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $8 HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $5 to $8.
- benzinga.com Savara Reveals That The Results From The Phase 3 Impala-2 Clinical Trial Will Be Published Online In NEJM; In The Largest Clinical Trial Conducted In Autoimmune PAP, Molgramostim Inhalation Solution Reduced Surfactant Burden And Improved Pulmonary Gas Transfer, Respiratory Health-Related Quality Of Life, And Patient Functionality Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be…
- benzinga.com Savara Announces It Will Present New Data From Phase 3 IMPALA-2 Trial Of Molgramostim Inhalation Solution In Patients With Autoimmune Pulmonary Alveolar Proteinosis At European Respiratory Society Congress 2025 Savara's Partner, TrilliumBiO, to Present Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP —Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage…
- benzinga.com Oppenheimer Maintains Outperform on Savara, Raises Price Target to $6 Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $5 to $6.
- benzinga.com HC Wainwright & Co. Upgrades Savara to Buy, Raises Price Target to $5 HC Wainwright & Co. analyst Andrew S. Fein upgrades Savara (NASDAQ:SVRA) from Neutral to Buy and raises the price target from $2 to $5.
- benzinga.com Savara Q2 EPS $(0.14) Misses $(0.12) Estimate Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 14.75 percent. This is a 16.67 percent decrease over losses of $(0.12)…
benzinga.com This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - benzinga.com HC Wainwright & Co. Downgrades Savara to Neutral, Lowers Price Target to $2 HC Wainwright & Co. analyst Andrew Fein downgrades Savara (NASDAQ:SVRA) from Buy to Neutral and lowers the price target from $6 to $2.
- benzinga.com HC Wainwright & Co. Downgrades Savara to Neutral, Lowers Price Target to $2 HC Wainwright & Co. analyst Andrew Fein downgrades Savara (NASDAQ:SVRA) from Buy to Neutral and lowers the price target from $6 to $2.
- benzinga.com Evercore ISI Group Maintains In-Line on Savara, Lowers Price Target to $2 Evercore ISI Group analyst Liisa Bayko maintains Savara (NASDAQ:SVRA) with a In-Line and lowers the price target from $3 to $2.
- benzinga.com Guggenheim Maintains Buy on Savara, Lowers Price Target to $8 Guggenheim analyst Vamil Divan maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $9 to $8.
- benzinga.com Wells Fargo Maintains Overweight on Savara, Lowers Price Target to $7 Wells Fargo analyst Tiago Fauth maintains Savara (NASDAQ:SVRA) with a Overweight and lowers the price target from $8 to $7.
benzinga.com Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Surges Over 600 Points; US Durable Goods Orders Fall in April 
benzinga.com Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings